Sun Pharma's Ilumya gets FDA approval

3/22/2018
The Food and Drug Administration has approved Sun Pharma's Ilumya (tildrakizumab-asmn). The biologic drug is indicated to treat moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” Sun Pharma president and CEO, North America, Abhay Gandhi said. “We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis.”

Ilumya is meant to be administered in a 100-mg dose every 12 weeks after two intial doses four weeks apart.
X
This ad will auto-close in 10 seconds